BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37021793)

  • 1. Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy.
    Aldoss I; Gu Z; Afkhami M; Mokhtari S; Pullarkat V
    Leuk Lymphoma; 2023 Jun; 64(6):1092-1101. PubMed ID: 37021793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
    Gupta DG; Varma N; Abdulkadir SA; Sreedharanunni S; Sachdeva MUS; Naseem S; Bose P; Binota J; Malhotra P; Khadwal A; Trehan A; Varma S
    Cancer; 2024 Mar; 130(5):713-726. PubMed ID: 37819686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adults with Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission.
    Aldoss I; Kamal MO; Forman SJ; Pullarkat V
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):e41-e45. PubMed ID: 30292743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.
    Jabbour E; Haddad FG; Short NJ; Kantarjian H
    JAMA Oncol; 2022 Sep; 8(9):1340-1348. PubMed ID: 35834222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xie M; Shi T; Jiang Q; Jia Y; Zhou D; Tong H; Jin J; Zhu HH
    Cancer; 2023 May; 129(10):1523-1536. PubMed ID: 36882308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
    Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia.
    Kato K; Takagi S; Takano H; Tsunoda S; Watanabe O; Yamaguchi K; Kageyama K; Kaji D; Taya Y; Nishida A; Ishiwata K; Yamamoto H; Yamamoto G; Asano-Mori Y; Koike Y; Makino S; Wake A; Taniguchi S; Uchida N
    Int J Hematol; 2024 Feb; 119(2):205-209. PubMed ID: 38236369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
    Czyz A; Lewandowski K; Kroll R; Komarnicki M
    Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article.
    Alghandour R; Sakr DH; Shaaban Y
    Ann Hematol; 2023 Jun; 102(6):1287-1300. PubMed ID: 37129698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical screening for Ph-like ALL and the developing role of TKIs.
    Tran TH; Tasian SK
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):594-602. PubMed ID: 36485164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Short NJ; Kantarjian H; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):61-66. PubMed ID: 34561201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
    Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
    Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
    Lu XT
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.
    Pui CH; Roberts KG; Yang JJ; Mullighan CG
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):464-470. PubMed ID: 28842136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
    Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
    N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
    Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment strategy for Philadelphia chromosome-positive acute lymphoblastic leukemia in children].
    Shimada H
    Rinsho Ketsueki; 2022; 63(7):799-804. PubMed ID: 35922951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of an atypical BCR::ABL1 fusion in a patient with secondary B-cell acute lymphoblastic leukemia/lymphoma following multiple myeloma treatment.
    Miller K; Webster J; Imus P; Ament C; Hardy M; Zou YS
    Cancer Genet; 2023 Jun; 274-275():30-32. PubMed ID: 36966724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options.
    Khan M; Siddiqi R; Tran TH
    Semin Hematol; 2018 Oct; 55(4):235-241. PubMed ID: 30502852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.